Equities

Establishment Labs Holdings Inc

Establishment Labs Holdings Inc

Actions
  • Price (USD)47.38
  • Today's Change-5.19 / -9.87%
  • Shares traded427.18k
  • 1 Year change-37.57%
  • Beta1.2192
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.

  • Revenue in USD (TTM)165.15m
  • Net income in USD-78.50m
  • Incorporated2013
  • Employees908.00
  • Location
    Establishment Labs Holdings IncBuilding B15 And 25 Coyol Free ZoneALAJUELA VG1110Costa RicaCRI
  • Phone+506 24342400
  • Websitehttps://establishmentlabs.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Artivion Inc354.00m-30.57m842.95m1.50k--2.95--2.38-0.7496-0.74968.686.860.45531.605.30236,002.70-3.95-2.20-4.24-2.3664.7465.51-8.67-5.343.430.68090.5246--12.826.14-60.09--5.13--
Perspective Therapeutics Inc8.17m-25.10m862.77m88.00--4.18--105.59-0.1012-0.10120.03510.3520.09444.915.5592,852.27-29.01---31.19--22.96---307.18--2.55--0.0173--------------
Avanos Medical Inc673.30m-9.90m864.02m3.77k--0.698423.871.28-0.2092-1.3214.4326.770.3871.664.73178,546.80-0.5691-0.6527-0.6473-0.733856.3954.45-1.47-1.601.384.270.1196---1.580.6357-146.05---18.37--
MiMedx Group Inc321.48m55.80m905.26m895.0023.876.3114.122.820.25810.21922.190.9761.573.196.63359,192.2032.86-4.1442.03-5.9083.0183.6120.98-2.703.117.110.256--20.03-2.19310.29---26.47--
Coretag Inc0.00-39.35k1.13bn-----------0.4372-0.43720.00-0.930.00-------78,700.00--------------------------10.95------
AtriCure Inc399.25m-30.44m1.13bn1.20k--2.38--2.83-0.6569-0.65698.629.810.66581.748.39332,704.20-5.08-3.72-5.71-4.1075.2374.36-7.62-7.642.66-8.520.1301--20.8414.6434.49--46.56--
Adapthealth Corp3.20bn-678.90m1.24bn10.70k--0.8512--0.3887-5.06-5.0623.7711.000.657921.798.56299,082.00-13.87-4.34-15.48-4.8917.8218.28-21.09-6.470.9971.830.5978--7.73---1,169.99------
LeMaitre Vascular Inc193.48m30.11m1.40bn614.0046.654.6935.307.231.341.348.6313.340.58881.238.22315,120.509.169.0210.009.9365.6665.8315.5615.454.57--0.0040.4119.6912.8845.895.9618.9315.51
Warby Parker Inc669.77m-63.20m1.40bn2.14k--4.65--2.10-0.5376-0.53765.712.551.174.65416.78312,974.30-11.00---14.16--54.5357.49-9.44-14.531.86--0.00--11.9819.6742.75------
Establishment Labs Holdings Inc165.15m-78.50m1.44bn908.00--74.55--8.74-3.05-3.056.450.70510.68861.004.01181,884.40-32.73-33.22-40.93-41.1264.7864.73-47.53-43.191.67-13.080.9112--2.1321.96-4.38--69.16--
Inmode Ltd492.05m197.92m1.47bn581.007.521.857.392.982.302.305.739.380.65271.9014.19846,898.4026.2531.3229.0735.6483.6084.4640.2239.6512.48--0.000.008.3237.4922.5454.6513.10--
UFP Technologies Inc400.07m44.92m1.66bn3.09k37.325.8129.544.165.845.8451.9737.451.024.656.69129,347.2011.489.6913.4510.9528.0526.3311.2310.141.2815.860.1010.0013.0816.007.5025.7114.08--
Alphatec Holdings Inc482.26m-186.64m1.70bn839.00--22.00--3.53-1.54-1.543.980.73050.72731.447.06574,805.80-28.15-30.97-36.25-39.4764.3266.02-38.70-46.221.99-5.400.8345--37.4539.38-23.36--67.92--
Owens & Minor, Inc.10.33bn-41.30m1.84bn13.70k--1.997.490.1783-0.5479-0.5479136.3112.071.976.7215.18754,304.20-0.78821.32-1.182.0720.5616.48-0.39970.56140.52442.040.69440.7983.801.87-284.47--25.91--
Tandem Diabetes Care Inc747.72m-222.61m2.03bn2.40k--6.46--2.71-3.44-3.4411.514.780.74572.826.79311,549.20-22.20-10.08-27.07-12.2349.1751.77-29.77-11.593.02--0.4761---6.6832.39-135.33--76.81--
Data as of Apr 19 2024. Currency figures normalised to Establishment Labs Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

53.39%Per cent of shares held by top holders
HolderShares% Held
JW Asset Management LLCas of 31 Dec 20233.19m11.74%
RTW Investments LPas of 31 Dec 20232.49m9.17%
Nantahala Capital Management LLCas of 31 Dec 20232.47m9.08%
Brown Advisory LLCas of 31 Dec 20232.43m8.93%
Cowen & Co. LLCas of 31 Dec 2023939.95k3.46%
Rice, Hall, James & Associates LLCas of 31 Dec 2023750.91k2.76%
Morgan Stanley & Co. LLCas of 31 Dec 2023636.99k2.34%
JPMorgan Investment Management, Inc.as of 31 Dec 2023625.44k2.30%
Findell Capital Management LLCas of 31 Dec 2023567.00k2.08%
Pura Vida Investments LLCas of 31 Dec 2023417.99k1.54%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.